Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694175 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TDP1USP2ALOX15POLB | |
| SCHEMBL18025043 | 0.79 | TDP1 (0.38) | ALDH1A1TDP1USP2ALOX15POLB | |
| SCHEMBL21553949 | 0.77 | TDP1 (0.37) | ALDH1A1TDP1USP2ALOX15POLB | |
| SCHEMBL4267252 | 0.71 | MAPT (0.33) | ALDH1A1TDP1USP2ALOX15LMNA | |
| SCHEMBL10394015 | 0.69 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15MEN1 | |
| SCHEMBL15750244 | 0.67 | ALDH1A1 (0.32) | ALDH1A1TDP1USP2ALOX15SMN1; SMN2 | |
| SCHEMBL3532178 | 0.66 | EPHX2 (0.45) | ALDH1A1TDP1USP2ALOX15POLB | |
| SCHEMBL15750316 | 0.66 | USP2 (0.31) | ALDH1A1TDP1USP2ALOX15 | |
| SCHEMBL10934266 | 0.65 | ALDH1A1 (0.42) | ALDH1A1TDP1USP2ALOX15POLB | |
| SCHEMBL5571264 | 0.65 | KMT2A (0.52) | ALDH1A1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | ALDH1A1 935/4885TDP1 2839/4885USP2 393/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | ALDH1A1 935/4885TDP1 2839/4885USP2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.